Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: t
View:
Locations
United States
Maryland
Wilmer Eye Institute
RECRUITING
Baltimore
Contact Information
Primary
Amir H Kashani, MD, PhD
akashan1@jhmi.edu
410-502-2789
Backup
Ana C Martinez, MPH
acollaz5@jhmi.edu
410-502-2789
Time Frame
Start Date: 2019-10-01
Estimated Completion Date: 2026-09-01
Participants
Target number of participants: 1050
Treatments
Other: Controls
Subjects in this group do not have any ocular pathology and are also not hypertensive. Some subjects in this arm will undergo retinal vascular reactivity assessments.
Other: Diabetics with and without Diabetic Retinopathy Only
Subjects in this group only have diabetes with or without diabetic retinopathy. Some subjects in this arm will undergo retinal vascular reactivity assessments.
Other: Hypertension Only
Subjects in this group only have hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
Other: Diabetics w/ or w/o Diabetic Retinopathy & Hypertension
Subjects in this group have diabetes with or without diabetic retinopathy and hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
Sponsors
Collaborators: National Eye Institute (NEI)
Leads: Johns Hopkins University

This content was sourced from clinicaltrials.gov